Aldeyra Therapeutics, Inc. - ALDX STOCK NEWS

Aldeyra Therapeutics announced promising signs of clinical activity for ADX-629 in three Phase 2 trials aimed at immune-mediated diseases. No safety issues were reported, and the company plans to expand ADX-629's development into new indications, including ethanol toxicity and chronic cough. Key results showed significant decreases in inflammation-related metrics in psoriasis, asthma, and COVID-19 patients. The company will present additional findings and plans during its R&D Day and expects to initiate new trials in 2023.

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) will hold a Research & Development Day on March 29, 2022, from 10:00 a.m. to 12:30 p.m. ET in New York City. The event will reveal top-line data from Phase 2 clinical trials of ADX-629, a first-in-class orally administered RASP modulator, targeting three inflammatory diseases. Presentations will feature Aldeyra's senior leadership and Dr. Geoffrey M. Thiele from the University of Nebraska Medical Center. A live webcast will be available on their website, with replays for 90 days.

Aldeyra Therapeutics (ALDX) reported its financial results for 2021, highlighting a net loss of $57.8 million, or $1.07 per share, compared to $37.6 million, or $1.11 per share in 2020. The increase in loss is attributed to higher costs in clinical trials and R&D, totaling $44.9 million. As of December 31, 2021, cash and cash equivalents stood at $229.8 million, projected to support operations through 2023. Upcoming milestones include top-line data from ADX-629 trials by March 2022 and results from various Phase 3 trials for reproxalap and ADX-2191 expected throughout 2022.

Aldeyra Therapeutics (Nasdaq: ALDX) announced that its CEO, Todd C. Brady, will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference conducted virtually from March 15-17, 2022. The discussion with analyst Justin Kim is set for 11:20 a.m. ET on March 16, 2022, and will be accessible via a webcast on Aldeyra's website, where it will remain archived for 90 days. Aldeyra focuses on therapies for immune-mediated diseases, with key products in various clinical trial phases.

Aldeyra Therapeutics (NASDAQ: ALDX) announced a conference call on March 17, 2022, at 8:00 a.m. ET to discuss its financial results for the year ended December 31, 2021, along with recent corporate highlights. The call will be accessible via dial-in and a live webcast on the company’s website. Aldeyra is focused on developing therapies for immune-mediated diseases, with key candidates reproxalap in Phase 3 trials for dry eye disease and ADX-629 in Phase 2 trials for psoriasis and COVID-19. More information is available on their website.

Aldeyra Therapeutics (NASDAQ: ALDX) has initiated a Phase 2 clinical trial for ADX-2191, an investigational drug for treating retinitis pigmentosa (RP), a rare genetic eye disease affecting 82,000-110,000 individuals in the U.S. The trial will evaluate the safety and tolerability of ADX-2191 in eight patients with rhodopsin mutations. Results are expected in the second half of 2022. ADX-2191 has received orphan drug designation from the FDA, which provides various incentives including market exclusivity upon approval.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) will have its President and CEO, Todd C. Brady, M.D., Ph.D., participate in a fireside chat at the SVB Leerink 2022 Global Healthcare Conference. The discussion, moderated by Marc Goodman from SVB Leerink, will be available on demand starting at 9:20 a.m. ET on February 16, 2022. Interested parties can access the webcast through the Investors & Media section of Aldeyra's website, where it will remain archived for 90 days. Aldeyra focuses on innovative therapies for immune-mediated diseases with drug candidates like reproxalap and ADX-629 in clinical trials.

Aldeyra Therapeutics (ALDX) announced the publication of positive results from a Phase 2 clinical trial of reproxalap for allergic conjunctivitis in the journal Clinical Ophthalmology. The trial demonstrated that reproxalap significantly improves ocular itching, tearing, and redness compared to the vehicle. Conducted with 70 adults, the trial showed sustained symptom relief up to an hour post-exposure to allergens. Reproxalap is currently in Phase 3 trials for dry eye disease and allergic conjunctivitis, addressing a significant unmet need in treating these conditions.

Aldeyra Therapeutics (Nasdaq: ALDX) announced positive results from a Phase 2 clinical trial of reproxalap, a treatment for dry eye disease. The trial demonstrated statistically significant reductions in ocular discomfort (p=0.002) and itching (p=0.01) compared to Xiidra. Reproxalap, a novel RASP modulator, had no safety concerns reported. This data suggests reproxalap's potential as a first-line therapy. The trial included 56 patients and indicated improved tolerability over existing treatments, addressing compliance issues that often arise with current therapies.